標(biāo)題: Titlebook: Management of Bone Disease and Kidney Failure in Multiple Myeloma; A Pocket Guide Elena Zamagni Book 2021 Springer Nature Switzerland AG 20 [打印本頁(yè)] 作者: Cyclone 時(shí)間: 2025-3-21 17:34
書目名稱Management of Bone Disease and Kidney Failure in Multiple Myeloma影響因子(影響力)
書目名稱Management of Bone Disease and Kidney Failure in Multiple Myeloma影響因子(影響力)學(xué)科排名
書目名稱Management of Bone Disease and Kidney Failure in Multiple Myeloma網(wǎng)絡(luò)公開度
書目名稱Management of Bone Disease and Kidney Failure in Multiple Myeloma網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Management of Bone Disease and Kidney Failure in Multiple Myeloma被引頻次
書目名稱Management of Bone Disease and Kidney Failure in Multiple Myeloma被引頻次學(xué)科排名
書目名稱Management of Bone Disease and Kidney Failure in Multiple Myeloma年度引用
書目名稱Management of Bone Disease and Kidney Failure in Multiple Myeloma年度引用學(xué)科排名
書目名稱Management of Bone Disease and Kidney Failure in Multiple Myeloma讀者反饋
書目名稱Management of Bone Disease and Kidney Failure in Multiple Myeloma讀者反饋學(xué)科排名
作者: Mnemonics 時(shí)間: 2025-3-21 21:02 作者: 虛度 時(shí)間: 2025-3-22 00:52
y experts in the fieldThis pocket guide provides a concise yet comprehensive overview of the two most prominent clinical features of multiple myeloma (MM), bone disease and renal failure. The first half of the text reviews critical aspects of bone disease in MM, including pathophysiology, the use of作者: BYRE 時(shí)間: 2025-3-22 08:39 作者: thrombus 時(shí)間: 2025-3-22 12:09
The Pathophysiology of Myeloma Bone Disease: Role of Osteoblasts and Osteocytes,sion of OB formation. Finally, it was recently shown that MM cells induce osteocyte death that in turn triggers the production of pro-osteoclastogenic cytokines and inhibitors of bone formation as sclerostin. These pathophysiological mechanisms are summarized in this chapter.作者: 考古學(xué) 時(shí)間: 2025-3-22 13:14
The Pathophysiology of Myeloma Bone Disease: Bone Remodelling and the Role of Osteoclasts,are disrupted in myeloma and can therefore be implicated in the evolution of bone destruction in this disease. As these pathways become clearer, they open up the possibility of targeted interventions which are explored elsewhere in this text.作者: congenial 時(shí)間: 2025-3-22 19:04 作者: Habituate 時(shí)間: 2025-3-22 22:50 作者: Frenetic 時(shí)間: 2025-3-23 04:13 作者: dyspareunia 時(shí)間: 2025-3-23 07:43
Cristina Nannies erprobten Effizienzkonzeptes zur situativ passenden Organisationsform führt. Der vorgestellte Ansatz ist wissenschaftlich-p?dagogisch fundiert und gleichzeitig praktisch gereift. In einer Zeit, in der massive Umweltturbulenzen und eine hybride Organisationsrealit?t die organisatorische Gestaltung作者: colony 時(shí)間: 2025-3-23 09:52
Leo Rasche,Anke Heidemeier,Stefan Delorme,Niels Weinholdelchem Kontext der Begriff verwendet wird, und insbesondere, aus welchem Grund und mit welchem Ziel Coaching in Anspruch genommen wird. Entscheidend ist dabei auch die theoretische Ausrichtung, die dem gew?hlten Ansatz zugrunde liegt. Gerade für den Umgang mit den aktuellen Herausforderungen hat sic作者: Mnemonics 時(shí)間: 2025-3-23 16:50
Introduction: Management of Bone Disease and Kidney Failure in Multiple Myeloma,noclonal immunoglobulin (M component, MC) in the bone marrow (BM) or, more rarely, in extramedullary tissues. Clinical signs and symptoms at the onset of MM are varied and typically related to the expansion of the neoplastic mass and/or the production by neoplastic cells of cytokines or other factor作者: RUPT 時(shí)間: 2025-3-23 20:47
The Pathophysiology of Myeloma Bone Disease: Bone Remodelling and the Role of Osteoclasts,he vast majority, this is irreversible and significantly adds to the already heavy disease burden. Over the last decade, the pathophysiology and complexity of bone destruction in myeloma have become increasingly evident, here we explore the multiple normal physiological pathways and cell types that 作者: Unsaturated-Fat 時(shí)間: 2025-3-24 00:06
The Pathophysiology of Myeloma Bone Disease: Role of Osteoblasts and Osteocytes,ll infiltration that induces an increased osteoclast (OCL) recruitment and activity, together with the suppression of bone formation. The hallmark of osteolytic lesions in MM is the lack of bone healing due to the suppression of the bone formation process..Osteoblast (OB) formation is impaired by th作者: 讓你明白 時(shí)間: 2025-3-24 05:28 作者: 項(xiàng)目 時(shí)間: 2025-3-24 08:55
Imaging Techniques for Response Assessment and Follow-Up,ent at the iliac crest. This type of heterogeneity can potentially lead to spatial differences in response to anti-MM therapy, highlighting the issue that bone marrow (BM) specimens from a single site are not always representative for the entire BM cavity. Medical imaging could be the key to overcom作者: filial 時(shí)間: 2025-3-24 10:58
New Perspectives in Imaging Techniques,(PET) imaging tracers are needed to overcome limitations of .fluoro-deoxyglucose (FDG), in order to improve tumor characterization by targeting other metabolic pathways or biomarkers expressed by neoplasm’s cells. .C-Methionine, which uptake reflects the increased protein synthesis of malignant cell作者: 駕駛 時(shí)間: 2025-3-24 15:17
Therapy of Myeloma Bone Disease,evelopment of myeloma-related bone disease. Along with other factors, they participate in increased osteoclast activity, decreased osteoblast function, and immunosuppressed marrow microenvironment that deregulate bone turnover and result in bone loss and skeletal-related events. Bisphosphonates are 作者: URN 時(shí)間: 2025-3-24 19:19
Orthopaedic Management in Multiple Myeloma: What Is the Role and When?,all with pathological fracture or via the fracture clinic following episodes of pain or functional loss. It is therefore imperative that both haematologists and orthopaedic surgeons have an appreciation the diagnostic principles related to the management of skeletal-related events, in order to offer作者: VEN 時(shí)間: 2025-3-24 23:48 作者: Default 時(shí)間: 2025-3-25 05:34
Treatment of Multiple Myeloma with Kidney Involvement, treated for myeloma?– a deep response that translates into a prolonged response with an improved quality of life. However, there is also an extremely important second goal?– particularly for those on renal replacement therapy with dialysis– and that is improvement in renal function such that dialys作者: Offbeat 時(shí)間: 2025-3-25 09:38
https://doi.org/10.1007/978-3-030-63662-3osteoblast; WBLDCT; WBMRI; FDG-PET/CT; orthopedic surgery作者: 四海為家的人 時(shí)間: 2025-3-25 12:57
978-3-030-63661-6Springer Nature Switzerland AG 2021作者: 軟弱 時(shí)間: 2025-3-25 18:22
Elena ZamagniOne of the first dedicated resources on the most prominent aspects of multiple myeloma.Presented in a concise, easy-to-read format.Written by experts in the field作者: Ergots 時(shí)間: 2025-3-26 00:01
http://image.papertrans.cn/m/image/622445.jpg作者: Ccu106 時(shí)間: 2025-3-26 00:23
Cristina Nannin die Autoren aufgrund ihrer vielf?ltigen praktischen Erfahrungen Potenziale für die Weiterentwicklung. Fokus sind eine Differenzierung des Ansatzes je nach strategischer Ebene zur verbesserten Unterscheidung von Effektivit?t und Effizienz sowie die Einbindung von Experimenten und Tests zur Beschleu作者: ANTIC 時(shí)間: 2025-3-26 06:36 作者: 簡(jiǎn)潔 時(shí)間: 2025-3-26 08:27 作者: HEPA-filter 時(shí)間: 2025-3-26 13:57 作者: Indecisive 時(shí)間: 2025-3-26 20:21 作者: 合適 時(shí)間: 2025-3-26 23:59 作者: 館長(zhǎng) 時(shí)間: 2025-3-27 04:19 作者: Madrigal 時(shí)間: 2025-3-27 08:51 作者: 小隔間 時(shí)間: 2025-3-27 10:16
Management of Bone Disease and Kidney Failure in Multiple MyelomaA Pocket Guide作者: cultivated 時(shí)間: 2025-3-27 14:14
Management of Bone Disease and Kidney Failure in Multiple Myeloma978-3-030-63662-3作者: 過于光澤 時(shí)間: 2025-3-27 18:59
Rebecca E. Andrews,Andrew D. Chantry,A. John Ashcroft作者: 推遲 時(shí)間: 2025-3-28 00:16
Bastien Jamet,Clément Bailly,Thomas Carlier,Anne-Victoire Michaud,Cyrille Touzeau,Philippe Moreau,Ca作者: Palpate 時(shí)間: 2025-3-28 02:43
Valeria Corradetti,Giorgia Comai,Claudia Bini,Gaetano La Manna作者: faction 時(shí)間: 2025-3-28 07:09 作者: locus-ceruleus 時(shí)間: 2025-3-28 12:00
8樓作者: Morose 時(shí)間: 2025-3-28 18:22
9樓作者: Mammal 時(shí)間: 2025-3-28 19:51
9樓作者: Largess 時(shí)間: 2025-3-28 23:41
9樓作者: 吵鬧 時(shí)間: 2025-3-29 03:07
9樓作者: 清唱?jiǎng)?nbsp; 時(shí)間: 2025-3-29 08:45
10樓作者: CODE 時(shí)間: 2025-3-29 12:59
10樓作者: Mast-Cell 時(shí)間: 2025-3-29 16:26
10樓作者: 拍下盜公款 時(shí)間: 2025-3-29 22:36
10樓
